Overview

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The goal of anti-HIV therapy is to prevent HIV from replicating. Long-term control of HIV requires at least two anti-HIV drugs that are active against the virus. Drug resistance is a problem for many treatment-experienced, HIV-infected people. The purpose of this study was to determine the benefit of adding a nucleoside reverse transcriptase inhibitor (NRTI) to a new anti-HIV drug regimen for the suppression of HIV.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
AIDS Clinical Trials Group
Treatments:
Darunavir
Enfuvirtide
Etravirine
Maraviroc
Raltegravir Potassium
Tipranavir